CD274 and non-small cell lung carcinoma: The availability of immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 or cytotoxic T-lymphocyte antigen 4 (CTLA-4) has revolutionized the treatment of NSCLC in the last decade.